

BSE Limited Corporate Relations Department P J Towers, Dalal Street Mumbai - 400 001 Scrip Code: 532300	National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 NSE Symbol: WOCKPHARMA
--	--

Dear Sir/Madam,

Sub: Intimation pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Pursuant to Regulation 30 read with Schedule III of Listing Regulations, this is to inform that the Company has received a Settlement Order No. SO/VV/AS/2023-24/7028 dated 22nd May 2023 ("Settlement Order") from the Securities and Exchange Board of India in the matter of SEBI Show Cause Notice dated September 15, 2022 bearing reference number SEBI/HO/EAD-8/AS/GD/2022/48506/5 in the matter of non-disclosure of interim outcome of USFDA inspection in the year 2013.

The Show Cause Notice pertained to a decade old incident, hence, in order to remain focused towards the Company's business which needed greater attention of Directors of the Company, a Settlement Application was submitted by the Company and the concerned directors on December 5, 2022 to SEBI without admitting or denying to any allegations and only to put *quietus* to the matter in accordance with law.

Vide the Settlement Order the charges contained in the said Show Cause Notice against the Company and its Directors viz. Dr. Habil Khorakiwala, Dr. Murtaza Khorakiwala and Dr. Huzaifa Khorakiwala have been disposed of without admission or denial of findings of fact and conclusions of law contained in the Show Cause Notice.

The settlement terms include payment of an amount of INR 36,70,875 in respect of the Company and INR 13,32,500 each on behalf of the Directors. There is no material impact of such settlement on the financial position of the Company.

Kindly take the above information on record.

Thanking you,

For Wockhardt Limited

Debashis Dey
Company Secretary

